Infections caused by gram-negative bacilli have assumed the major role in causing hospital infections, replacing the staphylococcus. Debilitated patients have been particularly susceptible to Pseudomonas aeruginosa infections. Polymyxins (B and E) and gentamicin have had restricted usefulness because of serious renal and otic toxicity. Recently, a new semisynthetic penicillin, carbenicillin, has been found to be active against Pseudomonas strains and indole-positive Proteus strains (1) . Carbenicillin has been administered in high doses to seriously ill patients with Pseudomonas infections with excellent clinical results (3) . However, reports of resistance to carbenicillin have begun to appear (2) . We have now examined the in vitro activity of 6-[D(-)-a-carboxy-3-thienylacetamido] penicillanic acid, BRL2288, against a variety of gram-negative bacilli.
MATERIALS AND METHODS
6-[D(-)-a-Carboxy-3-thienylacetamido) penicillanic acid, BRL2288 (Fig. 1 Susceptibility testing methods. Minimal inhibitory concentration (MIC) values were determined by tube dilution and agar dilution tests. In the tube dilution method, 0.5 ml of a 10-5 dilution of an overnight culture was used for the inoculum. Incubation was for 18 hr at 35 C. In the agar dilution method the antibiotic was incorporated into Trypticase Soy Agar (BBL). After the plates solidified, the surface was inoculated with an undiluted overnight culture; the end point was read as the lowest concentration that showed visible growth after overnight incubation at 35 C.
Assays for BRL2288 remaining in the supernatant of cultures were performed by using the agar diffusion method in plates (12 inch by 12 inch) with 5-mm wells in the agar. A 5-ml inoculum of an overnight culture of P. aeruginosa (ATCC23389) was added to the Trypticase Soy Agar before pouring the plate. Each plate contained a set of BRL2288 standards in concentrations of 5, 10, 20, and 40 jug/ml. The zone diameter was read with calipers, and a standard curve was constructed for the BRL2288 standard by plotting the logarithm of the drug concentration against zone size. coli were sensitive to 12.5 4g or less of the antibiotic per ml. Of the ampicillin-resistant E. coli, 28% were sensitive to 12.5 ,ug or less, 38% to 25 ,ug and 55% to 100 lg of BRL2288 per ml. The sensitivity of Fnterobacter species to BRL2288 was surprising with 65% sensitive to 12.5 ,ug/m1 and 91 % sensitive to 100 lOg/ml. Proteus mirabilis species fell into two groups, either very sensitive (i.e., less than 6.25 Aug/ml) or resistant (i.e., greater than 100 ,g/ml). All of the indole-positive Proteus strains tested i.e., morganii, vulgaris, and rettgeri) were sensitive to less than 6.25 ,ug/mL Rare Serratia strains were sensitive to BRL2288 but the majority of strains were extremely resistant.
The comparison of carbenicillin and BRL2288 (Fig. 3) demonstrates that BRL2288 is consistently one tube, twofold, more active than carbenicillin. This was also seen with Enterobacter species but was not seen for Proteus or E. coli species in which there was rarely even one tube difference in the MIC.
The activity of BRL2288 against most P. aeruginosa and some strains of E. coli and P. mirabilis was influenced by the size of the inoculum (Table 1) . BRL2288 was two-to fourfold less active in tube dilutions at an inoculum of 10 as at an inoculum of 10-. With the agar plate method, use of an undiluted overnight culture re- The synergism between BRL2288 and gentamicin was examined for strains with MIC for BRL-2288 from 15 to 250 Ag/ml, and MIC for gentamicin from 0.5 to 2.5 ,g/ml. Significant synergy was encountered in most strains examined (Fig.   6 ).
Combinations of BRL2288 and cloxacillin, a penicillinase-resistant penicillin, failed to show synergy against Pseudomonas or penicillinaseproducing E. coli and Klebsiella strains.
The activity of BRL2288 against gram-positive cocci is shown in Fig. 7 The synergy seen with combination of BRL-2288 and gentamicin is similar to that of carbenicillin (9) . It is probably related to the fact that the gentamicin is active against the colonies that persist and eventually overgrow in the tube dilution assay. The absence of synergy with penicillinaseresistant penicillin is similar to that which we reported with carbenicillin (5) .
Pseudomonas, Enterobacter, and indole-positive Proteus strains resistant to carbenicillin will be resistant to BRL2288. E. coli and P. mirabilis strains which are resistant to ampicillin will, in the majority of instances, be resistant to carbenicillin and BRL2288.
It is possible that BRL2288 might offer some aid in the treatment of Pseudomonas, Proteus, and Enterobacter infections, since it may be possible to maintain bactericidal levels more readily than with carbenicillin. The synergy shown with gentamicin would be effective in overcoming problems of resistance development and superinfection with Klebsiella (4). However, Smith and Finland (9) showed that carbenicillin resistance increased despite use of carbenicillin and gentamicin. Animal experiments should be performed to determine whether the in vitro superiority of BRL2288 as compared with carbenicillin against Pseudomonas is seen in vivo.
